Skip to main content
. 2012 Feb 13;109(9):3469–3474. doi: 10.1073/pnas.1201031109

Fig. 4.

Fig. 4.

Treatment with CCG-2979 improves survival in an in vivo mouse model for GAS infection. (A) Effect on survival of CCG-2979 [12.7 nmol (5 μg) per mouse] injected daily for 5 d beginning 24 h after infection of PLGTg+ mice with UMAA2616. Data were pooled from four independent experiments (with GAS inoculation of 8.3, 2.8, 3.6, or 4.0 × 105 cfu/mouse, respectively). A total of 27 mice were represented in the control group treated with vehicle alone (solid line), and 27 mice were represented in the CCG-2979–treated group (dashed line). (B) The same model as in A except that CCG-2979 was injected at a dose of 101.4 nmol (40 μg) per mouse per day for 4 d. Data were pooled from three independent experiments (with GAS inoculation of 4.22, 3.16, or 1.24 × 106 cfu/mouse, respectively). A total of 22 mice were represented in the control group (solid line), and 19 mice were represented in the CCG-2979–treated group (dashed line). (C) Pooled data from A and B, including all data for CCG-2979. (D) Pooled data for both compounds. CCG-102487 [93.3 nmol (40 μg) per mouse] was injected daily for 4 d beginning 24 h after infection of PLGTg+ mice with UMAA2616. Data for CCG-102487 (dotted line) are from one experiment (total of 10 mice with GAS inoculation of 4.22 × 106 cfu/mouse). P values were calculated with all pairwise multiple comparison procedures (Bonferroni method).